APR 01, 2015 8:13 AM PDT

Low Vitamin D Linked to Worse Prognosis in Type of Non-Hodgkin Lymphoma

WRITTEN BY: Ilene Schneider
A new study found that people with lower vitamin D levels prior to treatment for follicular lymphoma succumb to the disease or face relapse earlier than patients with sufficient vitamin D levels in their blood.
People with lower vitamin D levels before treatment for follicular lymphoma succumb or face relapse earlier.
The Wilmot Cancer Institute investigation is believed to be the first to report that lack of vitamin D is a potentially modifiable risk factor for this type of cancer. The study was published by the Journal of Clinical Oncology.

Vitamin D's connection to cancer is an active research topic. Prior studies have shown a survival benefit among patients with higher vitamin D levels for diffuse large B-cell lymphoma and chronic lymphocytic leukemia. In addition, earlier peer-reviewed research at Wilmot showed that low vitamin D levels among women with breast cancer correlated with more aggressive tumors and poorer prognosis; and that vitamin D deficiency among African Americans might help to explain higher death rates from colorectal cancer. Currently, Wilmot investigators are evaluating whether weekly, high doses of vitamin D (50,000 IU) improves the side effects related to androgen deprivation therapy for prostate cancer in patients ages 65 and older.

Jonathan W. Friedberg, M.D., director of the Wilmot Cancer Institute, and Jennifer Kelly, M.P.H., Ph.D., an epidemiologist at the University of Rochester School of Medicine and Dentistry, led the collaborative follicular lymphoma study between SWOG, a component of the NCI-sponsored National Clinical Trials Network, and the Lymphoma Study Association (LYSA), based in France.

Researchers observed a total of 423 follicular lymphoma patients in two independent cohorts, who were followed for a minimum of 5 ½ years each. They measured the patients' baseline vitamin D blood levels before cancer treatment began, and then tracked and analyzed cancer survival data for each group.

Future research might support prescribing vitamin D supplements for patients at the earliest point of follicular lymphoma treatment, when patients are typically monitored closely but have not started active therapy, investigators concluded. They also suggested that vitamin D may represent a proxy or biomarker for better health going into cancer treatment.

Follicular lymphoma is generally incurable although it's slow-growing and many people live for years with the disease. Risk increases with age, and an estimated 19,000 people annually are diagnosed with FL. Treatments have improved recently, although a subset of patients have an aggressive form for which therapy is not as effective. Better ways to predict the course of the disease are needed, therefore-and this is where vitamin D levels might provide a previously unidentified but modifiable factor associated with prognosis, Friedberg said.

"Our data, replicated internationally, supports other published observations linking Vitamin D deficiency with inferior cancer outcomes," he said. "However, the mechanisms of this link are likely complex and require further study."

Large differences in vitamin D levels among the patients in the two cohorts prevented scientists from being able to recommend an optimal level of vitamin D for follicular lymphoma patients. (In the U.S., vitamin D sufficiency is usually defined as 25 mg/ml.) Geographic regions (including less sunny climates) and ethnicity and genetics (African Americans often have lower levels that other races) influence baseline vitamin D levels in people to a great extent, and would impact a threshold level.

Source: University of Rochester
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JAN 28, 2021
Cancer
Research shows 4 in 10 cancer deaths are from cigarette smoking
JAN 28, 2021
Research shows 4 in 10 cancer deaths are from cigarette smoking
No really, put down that cigarette. New research attributes 4 in 10 cancer deaths in the Southern US and Appalachia to c ...
JAN 31, 2021
Cancer
Exploring porphyrins as drug delivery agents
JAN 31, 2021
Exploring porphyrins as drug delivery agents
New research published in the journal Scientific Reports analyzes the delivery capabilities of porphyrins in order ...
FEB 18, 2021
Cancer
Measuring the psychological impacts of cancer and additional comorbidities
FEB 18, 2021
Measuring the psychological impacts of cancer and additional comorbidities
In a new analysis of 2017 data from the National Health Survey of Spain published in Psycho-Oncology, researchers find t ...
FEB 19, 2021
Cancer
Deep learning helps predict lung cancer
FEB 19, 2021
Deep learning helps predict lung cancer
A study from Penn State Great Valley researchers describes how a deep learning model could be used to predict the surviv ...
MAR 09, 2021
Cannabis Sciences
Cannabis Alleviates Neuropathic Pain from Chemotherapy
MAR 09, 2021
Cannabis Alleviates Neuropathic Pain from Chemotherapy
Neuropathic pain from oxaliplatin-based chemotherapy regimens occurs in up to 90% of patients, and continued exposure to ...
APR 10, 2021
Cancer
Administration of this immune-stimulating drug pre-surgery could help pancreatic cancer patients
APR 10, 2021
Administration of this immune-stimulating drug pre-surgery could help pancreatic cancer patients
New findings support the administration of a CD40 immune-stimulating drug to early-stage pancreatic cancer patients in a ...
Loading Comments...